AR030373A1 - Profarmacos para el tratamiento de enfermedades relacionadas con el receptor del nmda - Google Patents

Profarmacos para el tratamiento de enfermedades relacionadas con el receptor del nmda

Info

Publication number
AR030373A1
AR030373A1 ARP010103939A ARP010103939A AR030373A1 AR 030373 A1 AR030373 A1 AR 030373A1 AR P010103939 A ARP010103939 A AR P010103939A AR P010103939 A ARP010103939 A AR P010103939A AR 030373 A1 AR030373 A1 AR 030373A1
Authority
AR
Argentina
Prior art keywords
treatment
diseases related
propharms
formula
lower alkyl
Prior art date
Application number
ARP010103939A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Alanine
Bernd Buettelmann
Holger Fischer
Neidhart Marie Paule Heitz
Joerg Huwyler
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR030373A1 publication Critical patent/AR030373A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/42Oxygen atoms attached in position 3 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/59Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ARP010103939A 2000-08-21 2001-08-17 Profarmacos para el tratamiento de enfermedades relacionadas con el receptor del nmda AR030373A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21

Publications (1)

Publication Number Publication Date
AR030373A1 true AR030373A1 (es) 2003-08-20

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103939A AR030373A1 (es) 2000-08-21 2001-08-17 Profarmacos para el tratamiento de enfermedades relacionadas con el receptor del nmda

Country Status (35)

Country Link
US (1) US6407235B1 (enExample)
EP (1) EP1313703B1 (enExample)
JP (1) JP4162991B2 (enExample)
KR (1) KR100589991B1 (enExample)
CN (1) CN1227230C (enExample)
AR (1) AR030373A1 (enExample)
AT (1) ATE386022T1 (enExample)
AU (2) AU2001285894B2 (enExample)
BR (1) BR0113348A (enExample)
CA (1) CA2419279C (enExample)
CY (1) CY1107937T1 (enExample)
CZ (1) CZ303319B6 (enExample)
DE (1) DE60132782T2 (enExample)
DK (1) DK1313703T3 (enExample)
EC (1) ECSP034489A (enExample)
EG (1) EG24293A (enExample)
ES (1) ES2299508T3 (enExample)
HR (1) HRP20030125B1 (enExample)
HU (1) HU229802B1 (enExample)
IL (1) IL154254A0 (enExample)
JO (1) JO2289B1 (enExample)
MA (1) MA26947A1 (enExample)
MX (1) MXPA03001311A (enExample)
MY (1) MY136065A (enExample)
NO (1) NO324941B1 (enExample)
NZ (1) NZ523990A (enExample)
PA (1) PA8525601A1 (enExample)
PE (1) PE20020291A1 (enExample)
PL (1) PL204215B1 (enExample)
PT (1) PT1313703E (enExample)
RS (1) RS51467B (enExample)
RU (1) RU2272027C2 (enExample)
SI (1) SI1313703T1 (enExample)
WO (1) WO2002016321A1 (enExample)
ZA (1) ZA200300894B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300235A2 (hu) * 2000-03-21 2003-08-28 The Procter & Gamble Co. Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US8759400B2 (en) * 2005-12-19 2014-06-24 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
CN105683180B (zh) 2013-11-05 2020-01-21 阿斯利康(瑞典)有限公司 Nmda拮抗剂前药

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69420053T2 (de) * 1994-01-31 1999-11-25 Pfizer Inc., New York Neuroprotektive chroman verbindungen
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
ZA200300894B (en) 2004-04-30
BR0113348A (pt) 2003-07-08
JP2004506715A (ja) 2004-03-04
PL204215B1 (pl) 2009-12-31
ECSP034489A (es) 2003-03-31
EG24293A (en) 2009-01-08
RS51467B (sr) 2011-04-30
HRP20030125A2 (en) 2005-02-28
IL154254A0 (en) 2003-09-17
MY136065A (en) 2008-08-29
CZ2003492A3 (cs) 2004-01-14
EP1313703A1 (en) 2003-05-28
JP4162991B2 (ja) 2008-10-08
ES2299508T3 (es) 2008-06-01
CA2419279C (en) 2008-10-14
DK1313703T3 (da) 2008-05-19
DE60132782D1 (de) 2008-03-27
HUP0301548A2 (hu) 2003-08-28
DE60132782T2 (de) 2009-02-05
CN1227230C (zh) 2005-11-16
PT1313703E (pt) 2008-03-25
CZ303319B6 (cs) 2012-08-01
KR100589991B1 (ko) 2006-06-15
NZ523990A (en) 2004-09-24
KR20030022417A (ko) 2003-03-15
JO2289B1 (en) 2005-09-12
PA8525601A1 (es) 2002-04-25
AU2001285894B2 (en) 2006-06-15
PE20020291A1 (es) 2002-04-17
CN1447793A (zh) 2003-10-08
CA2419279A1 (en) 2002-02-28
US6407235B1 (en) 2002-06-18
RU2272027C2 (ru) 2006-03-20
EP1313703B1 (en) 2008-02-13
MA26947A1 (fr) 2004-12-20
NO20030781L (no) 2003-02-19
NO20030781D0 (no) 2003-02-19
CY1107937T1 (el) 2013-09-04
ATE386022T1 (de) 2008-03-15
US20020040037A1 (en) 2002-04-04
SI1313703T1 (sl) 2008-06-30
MXPA03001311A (es) 2003-06-30
AU8589401A (en) 2002-03-04
HRP20030125B1 (en) 2011-07-31
WO2002016321A1 (en) 2002-02-28
HUP0301548A3 (en) 2010-03-29
PL361387A1 (en) 2004-10-04
YU13003A (sh) 2006-05-25
HK1059083A1 (en) 2004-06-18
NO324941B1 (no) 2008-01-07
HU229802B1 (hu) 2014-07-28

Similar Documents

Publication Publication Date Title
UY26872A1 (es) Derivados de la 4- fenil piridina
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
UY27368A1 (es) Nuevos compuestos
EA200400981A1 (ru) Новые гетероциклические соединения, активные в качестве ингибиторов бета-лактамаз
AR041729A1 (es) Compuesto de cefemo
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
DOP2003000694A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PA8591701A1 (es) Derivados de pirrolopirimidina
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
AR048213A1 (es) 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol
PE20191784A1 (es) Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
UY27980A1 (es) Indoles 2,7-sustituidos
AR030373A1 (es) Profarmacos para el tratamiento de enfermedades relacionadas con el receptor del nmda
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
AR027578A1 (es) Derivados de indano
CO5570673A2 (es) Compuestos azapoliciclicos condensados con arilo
ECSP014079A (es) Derivados de sulfonamida
AR019197A1 (es) COMPUESTOS DERIVADOS DE PIPERIDINA ANTIHISTAMINICOS, COMPUESTOS INTERMEDIOS, PROCEDIMIENTO DE PREPARACIoN DE DERIVADOS DE PIPERIDINA Y PROCEDIMIENTOS DE PREPARACIoN DE INTERMEDIARIOS.
UY27560A1 (es) Compuestos hexaciclicos-

Legal Events

Date Code Title Description
FG Grant, registration